Skip to main content
. 2019 Jan 7;27(4):463–466. doi: 10.1016/j.jsps.2019.01.008

Table 2.

Frequencies and percentages of respondents to potential DDIs*

Drug –drug combinations Shouldn’t be used together Contra indication) n(%) May be used together with monitoring n(%) No interactions n(%) Not sure n(%)
Warfarin and cimetidine 169 (59.7) 81 (28.6) 21(7.4) 12(4.2)
Sildenafil and isosorbide mononitrate 211(74.6) 64(22.6) 6(2.1) 2(0.7)
Conjugated estrogens and raloxifen 66(23.3) 112(39.6) 77(27.2) 28(9.9)
Fexofenadine HCL and metoprolol 38(13.4) 84(29.7) 124(43.8) 37(13.1)
Theophylline and ciprofloxacin 113(39.9) 99(35) 53(18.7) 18(6.4)
Pimozide and ketoconazole 92(32.5) 127(44.9) 21(7.4) 43(15.2)
Methyldopa and phenobarbital 127(44.9) 80(28.3) 50(17.7) 26(9.2)
Phenytoin and cimetidine 148(52.3) 87(30.7) 23(8.1) 25(8.8)
Itraconazole and quinidine 107(37.8) 105(37.) 28(9.9) 42(14.9)
Amiodarone and simvastatin 72(25.4) 122(43.1) 63(22.3) 26(9.2)
Methotrexate and probenecid 60(21.2) 120(42.4) 54(19.1) 47(16.7)
Diphenhydramine and warfarin 45(15.9) 122(43.1) 87(30.7) 29(10.2)
Raloxifene and alendronate 30(10.6) 120(42.4) 91(32.2) 39(13.8)
Warfarin and diflunisal 82(29.0) 106(37.5) 31(11.0) 64(22.6)
Amiodarone and fluconazole 46(16.3) 96(33.9) 74(26.1) 67(23.7)
Theophylline and omeprazole 64(22.6) 77(27.2) 97(34.3) 45(15.9)
Sulfinpyrazone and warfarin 110(38.9) 89(31.4) 26(9.2) 58(20.5)
Meperidine and phenelzine 125(44.2) 54(19.1) 39(13.8) 65(23.0)
Fluconazole and phenytoin 109(38.5) 107(37.8) 44(15.5) 23(8.1)
Warfarin and nortriptyline 74(26.1) 146(51.6) 32(11.3) 31(11)
Amoxicillin and acetaminophen with codeine 18(6.4) 52(18.4) 197(69.6) 16(5.7)
Digoxin and clarithromycin 94(33.2) 113(39.9) 54(19.1) 22(7.8)
Alprazolam and itraconazole 72(25.4) 107(37.8) 60(21.2) 44(15.5)
Dopamine and phenytoin 76(26.9) 114(40.3) 36(12.7) 57(20.1)
Ciprofloxacin and tizanidine 70(24.7) 91(32.2) 57(20.1) 65(23.0)
Cyclosporine and rifampicin 102(36.0) 88(31.1) 39(13.8) 54(19.1)
*

Bold numbers are the corrected answers.